Computationally Designed avβ6 Binders for TGF-β Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targeting of alpha(v) beta (6) integrin (avb6) for treating avb6(+) tumors and pulmonary fibrosis such as Idiopathic Pulmonary Fibrosis (IPF), as existing treatments do not adequately address the role of avb6 in tumor progression and fibrosis.
Innovation Solution
Design and development of polypeptides with specific amino acid sequences that bind to avb6 integrin with high affinity, including sequences such as SEQ ID NOS:1-3, which can be used to treat avb6(+) tumors and block TGF-B signaling, thereby inhibiting tumor growth and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to target avb6, then treatment is provided, but the therapies lack specificity and efficacy resulting in poor overall survival
Solution Approach 1:
The patent uses computational design to create de novo protein binders that copy and mimic the natural ligand-binding interface of TGF-β1 with avβ6 integrin. These designed proteins replicate the specific molecular interactions (RGD motif binding to integrin) that naturally occur, achieving sub-nanomolar affinity while maintaining simplicity in therapeutic application
Solution Approach 2:
The patent systematically optimizes key parameters of the protein binders including affinity (achieving sub-nanomolar Kd), specificity (selective binding to avβ6 over other integrins), and stability (hyperstable de novo structures). These parameter optimizations resolve the contradiction by achieving high therapeutic efficacy through computationally tuned binding properties without increasing therapy complexity
2Reliability
If high affinity binders are designed to target avb6, then blocking of TGF-β signaling is achieved, but serum half-life may be extended causing systemic exposure
Solution Approach 1:
The patent employs aerosolized localized delivery to the lung tissue, creating a local concentration gradient where the binder acts primarily at the target site (avβ6-positive fibrotic tissue in lungs) rather than circulating systemically. This resolves the contradiction by maintaining high local affinity effects while minimizing systemic duration through localized administration
Solution Approach 2:
The patent extracts the essential binding function from full-length antibodies or complex TGF-β antagonists, creating minimal de novo protein binders that contain only the necessary RGD-containing binding domain. This simplified structure achieves high affinity while enabling shorter half-life and localized delivery, separating the binding function from unnecessary systemic circulation components
3Reliability
If specific avb6 targeting is achieved, then selective blocking of TGF-β signaling occurs, but current therapies lack the required specificity
Solution Approach 1:
The patent designs universal de novo protein binders with a standardized RGD-containing binding interface that specifically recognizes avβ6 integrin. This universal design approach achieves high specificity through computationally optimized sequence-structure relationships, resolving the contradiction by demonstrating that specific targeting can be achieved through rational design rather than complex empirical therapy development
Solution Approach 2:
The patent replaces empirical, trial-and-error therapeutic development with computational design algorithms that systematically optimize protein sequences for avβ6 binding. This substitution of computational mechanics for experimental mechanics achieves high specificity through in silico optimization of binding interfaces, reducing design complexity compared to iterative wet-lab approaches
Data Source
AI summary
Alpha(v) beta (6) integrin (avb6) binding polypeptides are disclosed herein, and their use in treating and detecting tumors, and their use in treating pulmonary fibrosis.